| Main Menu   | Home  |  About Us  |  What's New | FAQSite Search   | Contact Us   |  Books  | Privacy Policy | 

BIBLIOGRAPHY OF EDTA CHELATION THERAPY

A Selected Bibliography Prepared by Stephen F. Olmstead, M.D. Clinical Assistant Professor of Medicine, Division of Cardiology University of Washington School of Medicine Funded in part by a grant from the American College for the Advancement of Medicine

 

Ahrens FA and Aronson AL: A comparative study of the toxic effects of calcium and chromium chelates of ethylenediaminetetraacetate in the dog. Toxic Appl Pharmac 18:10, 1971.

Ahrens FA and Aronson AL: Toxicity of calcium ethylenediaminetetraacetate in dogs. Fed Proc Fedn Am Soc Exp Biol 27:1401, 1968.

Altman J, Wakim KG and Winkelmann RK: Effects of edathamil disodium on the kidney. J Invest Derm 38:215-218, 1962.

Angle CR and McIntire MS: Lead poisoning during pregnancy. Fetal tolerance of calcium disodium edetate . Am J Dis Child 108:436, 1964.

Aronov DM: First experience with the treatment of atherosclerosis patients with calcinosis of the arteries with Trilon B (disodium salt of EDTA) Klin Med (Moskva) 41:19-23, 1963.

Aronson AL and Ahrens FA: The mechanism of renal transport and excretion of ethylenediaminetetraacetate with interspecies comparison. Toxic Appl Pharmac 18:1, 1971.

Aronson AL and Hammond PB: Effect of two chelating agents on the distribution and excretion of lead. J Pharmacol Exp Ther 146:241-251, 1964.

Aronson AL, Hammond PB and Strafuss AC: Studies with calcium ethylenediaminetetraacetate in calves; toxicity and use in bovine lead poisoning. Toxicol Appl Pharmacol 12:337-349, 1968.

Batchelor TM, McCall M and Mosher RM: Potassium dieresis induced by edathamil disodium. JAMA 187:305, 1964.

Bates GW, Billups C and Saltman P: The kinetics and mechanism of iron (III) exchange between chelates and transferrin. II. The presentation and removal with ethylenediaminetetraacetate. J Biol Chem 242:2816, 1967.

Bauer RO, Rullo FR, Spooner C and Woodman E: Acute and subacute toxicity of ethylene diamine tetraacetic (EDTA) salts. Fed Proceed 2:321, 1952.

Bechtel JT, White JE and Estes EH Jr: The electrocardiographic effects of hypocalcemia induced in normal subjects with edathamil disodium. Circulation 13:837, 1956.

Berkman N, Michaeli Y, Or R and Eldor A: EDTA dependent pseudothrombocytopenia: a clinical study of 18 patients and a review of the literature. Am J Hematol 36:195, 1991.

Bessman SP, Ried H and Rubin M: Treatment of lead encephalopathy with calcium disodium versenate. Ann Med Soc DC 21:312, 1952.

Birk RE and Rupe CE: The treatment of systemic sclerosis with disodium EDTA, pyridoxine and reserpine. Henry Ford Hosp Med Bull 14:109, 1966.

Birk RE and Rupe CE: Systemic sclerosis. Fourteen cases treated with chelation (disodium EDTA) and/or pyridoxine, with comments on the possible role of altered tryptophan metabolism in pathogenesis. Henry Ford Hosp Med Bull 10:523, 1962.

Blumer W and Cranton EM: Ninety percent reduction in cancer mortality after chelation therapy with EDTA. J Adv Med 2:183 1989.

Bolick LE and Blankenhor, DH: A quantitative study of coronary arterial calcification. Am J Path 39:511, 1961.

Boyle AJ, Jasper JJ, McCormick H, et al: Studies in human and induced atherosclerosis employing - (EDTA). Bull Swiss Acad Med Sci 13:408, 1957.

Boyle AJ, Clark NE, Mosher RE and McCann DS: Chelation therapy in circulatory and sclerosing diseases. Fed Proc 20 (Suppl 10):243, 1961.

Boyle AJ, Mosher RE and McCann DS: Some in vivo effects of chelation. I. Rheumatoid arthritis. J Chron Dis 16:325, 1963.

Brien TG and Fay JA: 51Cr-EDTA biological half life as an index of renal function. (Letters) J Nucl Med 13:339, 1972.

Brecher A: Bye-Bye Bypass: The Truth About Chelation Therapy. Troup, Texas, Health Savers Press, 1989.

Brucknerova O and Malinovska V: First clinical experience with combined treatment with chelation III and glucagon in ischemic disease of the lower extremities. Cas Lek Cas 119:814, 1980.

Brucknerova O, Tulacek J and Krojzl O: Chelates in the treatment of obliterating arteriopathies. Vnitrni Lek 14:841, 1968.

Brucknerova O and Tulacek J: Chelates in the treatment of occlusive arteriosclerosis. Vnitrni Lek 18:729, 1972.

Brugsch HG: Fatal nephropathy during edathamil therapy in lead poisoning. AMA Arch Indust Health 20:285, 1959.

Calcium disodium edetate and disodium edetate. Drugs for human use; drug efficacy study implementation. Department of Health, Education, and Welfare. Food and Drug Administration. Federal Registrar 35 F.R. 437, 1970.

Casdorph HR: EDTA chelation therapy - efficacy in arteriosclerotic heart disease. J Holistic Med 3:53, 1981.

Casdorph HR: EDTA chelation therapy. II. Efficacy in brain disorders J Holistic Med 3:101, 1981.

Casdorph HR: Chelation therapy: a reappraisal. N Z Med J 66, 1983.

Casdorph HR and Farr CH: EDTA chelation therapy III: treatment of peripheral arterial occlusion, an alternative to amputation. J Holistic Med 5:3, 1983.

Cashion WR Jr: What about chelation? Texas Medicine 80:6, 1984.

Castellino N and Aloj S: Effects of calcium sodium ethylenediaminetetra-acetate on the kinetics of the distribution and excretion of lead in the rat. Brit J Indust Med 22:172, 1965.

Catsch A: Radioactive metal mobilization. Fed Proc 20 (Suppl 10):206, 1961.

Chaitlow L: Chelation Therapy: The Revolutionary Alternative to Heart Surgery. San Francisco, Thorsons SF, 1991.

Chantler C and Barratt TM: Estimation of glomerular filtration rate from plasma clearance of 51-chromium edetic acid. Arch Dis Child 47:613, 1972.

Chantler C, Garnett ES, Parsons V and Veall N: Glomerular filtration rate measurement in man by the single injection method using 51Cr-EDTA. Clin Sci 37:169, 1969.

Chappell LT and Stahl JP: The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis. J Adv Med 6:139, 1993.

Chappell LT: Chelation therapy, smoking and health care costs (Letter). J Adv Med 7:107, 1994.

Chappell LT: EDTA chelation therapy should be more commonly used in the treatment of vascular disease. Alternative Therapies Health Med 1:53, 1995.

Chappell LT, Miranda R, Rubin M, Carter JP and Trowbridge J: Chelation therapy (Letter). Circulation 92:1350, 1995.

Chelation therapy (Diagnostic and therapeutic technology assessment). JAMA 250:672, 1983.

Chelation therapy. Resolution: 66 (I-84). AMA House of Delegates. 1984.

Chelation therapy. Report of the Council on Scientific Affairs. Report F (I-84). AMA House of Delegates. 1984.

Chelation therapy - An informal summary. Department of Health & Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. Bethesda, Maryland. June 1992.

Chelation therapy: a second look. The Harvard Medical School Health Letter IX:1, 1984.

Chelation Therapy Clinic: Chelation Therapy - The Treatment of Choice for Relief From and Prevention of, Cardiovascular and Age-Related Diseases. Auckland, New Zealand, The Chelation Therapy Clinic, 1987.

Chen IW, Park HM, King LR, Bahr GK and Goldsmith RE: Radioimmunoassay of parathyroid hormone: peripheral plasma immunoreactive parathyroid hormone response to ethylenediaminetetraacetate. J Nucl Med 15:763, 1974.

Chisolm JJ Jr: Chelation therapy in children with subclinical plumbism. Pediatrics 53:441, 1974.

Chisolm JJ Jr: The use of chelating agents in the treatment of acute and chronic lead intoxication in childhood. J Pediat 73:1, 1968.

Clark NE Sr, Atherosclerosis, occlusive vascular disease and EDTA. (Ed) Am J Cardiol 6:233, 1960.

Clarke NE, Clarke CN, Mosher RE: The "in vivo" dissolution of metastatic calcium. An approach to atherosclerosis. Am J Med Sci 229:142, 1955.

Clarke NE, Clarke CN, Mosher RE: Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. Am J Med Sci 232:654, 1956.

Clarke NE Sr, Clarke NE Jr, Mosher RE: Treatment of occlusive vascular disease with disodium ethylene diamine tetraacetic acid (EDTA) Am J Med Sci, 239:732, 1960.

Clarke NE, Clarke CN, Mosher RE: The "in-vivo" dissolution of metastatic calcium: an approach to atherosclerosis. Am J Med Sci 229:142, 1955.

Clarke NE Sr: Atherosclerosis, occlusive vascular disease and EDTA. Am J Cardiol 6:233, 1960.

Cohen S, Weissler AM and Schoenfeld CD: Antagonism of the contractile effect of digitalis by EDTA in the normal human ventricle. Am Heart J 69:502, 1965.

Conti CR: Chelation therapy for atherosclerosis: one man's view. Clin Cardiol 18:545, 1995.

Couric JM: Chelation therapy overdone. FDA Consumer 16:28. 1982.

Cranton EM and Brecher A: Bypassing Bypass: The New Technique of Chelation Therapy. New York, Stein and Day, 1990.

Cranton EM: Kidney effects of ethylene diamine tetraacetic acid (EDTA): A literature review. J Holistic Med 4:152, 1982.

Cranton EM: The current status of EDTA chelation therapy. J Holistic Med 7:3, 1985.

Cranton EM: Protocol of the American College of Advancement in Medicine for the safe and effective administration of EDTA chelation therapy. J Adv Med 2:269, 1989.

Cranton EM: A textbook on EDTA chelation therapy. J Adv Med 2:1-416, 1989.

Cranton EM and Frackelton JP: Current status of EDTA chelation therapy in occlusive arterial disease. J Holistic Med 1:24, 1982.

Cranton EM and Frackelton JP: Free radical pathology in age-associated diseases: treatment with EDTA chelation, nutrition and antioxidants. J Holistic Med 6:6, 1984.

Cranton EM and Frackelton JP: Negative Danish study of EDTA chelation biased (Letter). Townsend Letter Doctors. July, 604-605, 1992.

Craven PC and Morrelli HF: Chelation therapy. West J Med 122:277, 1975.

Curran CL: Metal chelating agents and hepatic cholesterol synthesis. Proc Soc Exper Biol & Med 88:101, 1955.

Darwish NM and Kratzer FH: Metabolism of ethylenediaminetetraacetic acid (EDTA) by chickens. J Nutr 86:187, 1965.

Davis FA, Becker FO, Michael JA and Sorensen E: Effect of intravenous sodium bicarbonate disodium EDTA and hyperventilation on visual and oculomotor signs in multiple sclerosis. J Neurol Neuro-surg Psychiat 33:723, 1970.

Davis PS and Deller DJ: Effect of orally administered chelating agents EDTA, DTPA and fructose on radioiron absorption in man. Aust Ann Med 16:70, 1967.

Davis H and Moe PJ: Favorable response of calcinosis universalis to edathamil disodium. Pediatriacs 24:780, 1959.

Deucher DP: EDTA chelation therapy: an antioxidant strategy. J Adv Med 1:182, 1988.

Diagnostic and therapeutic technology assessment; chelation therapy. JAMA 250:672, 1983.

Donald GF, Hunter GA, Roman W and Taylor AEJ: Current concepts of cutaneous porphyria and its treatment with particular reference to the use of sodium calcium-edetate. Brit J Derm 82:70, 1970.

Donsbach KW: Chelation Therapy; Has the Plug Been Pulled on Our Biggest Killer? Huntington Beach, CA, International Institute of Health, 1981.

Doolan PD, Schwartz SL, Hayes JR, Mullen JC and Cummings NB: An evaluation of the nephrotoxicity of ethylenediaminetetraacetate in the rat. Toxicol Appl Pharmacol 10:481, 1967.

Dudley HR, Ritchie AC, Schilling A and Baker WH: Pathologic changes associated with the use of sodium ethylene diamine tetra-acetate in the treatment of hypercalcemia. N Eng J Med 252:331, 1955.

EDTA chelation therapy for arteriosclerotic heart disease. Medical Letter 23:51 l981.

EDTA chelation: a rebuttal. J Adv Med 5:3, 1992.

EDTA chelation therapy for atherosclerotic cardiovascular disease. Medical Letter 36:48 l994.

Eliot RS and Blout SG Jr: Calcium, chelates and digitalis. A clinical study. Am Heart J 62:7, 1961.

Emmerson BT: Chronic lead nephropathy. The diagnostic use of calcium EDTA and the association with gout. Aust Ann Med 12:310, 1963.

Estep HL, Gardner CT Jr, Taylor JP, Minott A and Tucker HStG Jr: Phosphate excretion patterns following intravenous injection of ethylenediaminetetraacetate ((EDTA). J Clin Endocr 25:1385, 1965.

Favre HR and Wing AJ: Simultaneous 51Cr edetic acid, inulin, and endogenous creatinine clearances in 20 patients with renal disease. Brit Med J 1:84, 1968.

Feigen RD, Shannon DC, Reynolds SL, Shapiro LW and Connelly JP: Lead poisoning in children. Clin Pediat 4:38, 1965.

Fink CW and Baum J: Treatment of calcinosis universalis with chelating agents. Am J Dis Child 105:390, 1963.

Flynn DM: 5-year controlled trial of chelating agents in treatment of thalassaemia major. Arch Dis Child 48:829, 1973.

Foreman H: Pharmacology of Some Useful Chelating Agents. In Seven MJ and Johnson LA (eds): Metal-Binding in Medicine. Philadelphia, JB Lippincott, 1960.

Foreman H: Summary remarks by the chairman. [Proceedings of a conference on biological apects of metal-binding.] Fed Proc 20 (Suppl 10):257, 1961.

Foreman H: Use of chelating agents in treatment of metal poisoning with special emphsis on lead). Fed Proc 20 (Suppl 10):191, 1961.

Foreman H: Toxic side effects of ethylenediaminetetraacetic acid. J Chron Dis 16:319, 1963.

Foreman H, Vier M and Magee M: The metabolism of C14 labeled ethylenediaminetetraacetic acid in the rat. J Biol Chem 203:1045, 1953.

Foreman H, Finnegan C and Lushbaugh CC: Nephrotoxic hazard from uncontrolled edathamil calcium-disodium therapy. JAMA 160:1042, 1956.

Foreman H and Trujillo TT: The metabolism of 14C-labelled ethylene diaminetetraacetic acid in human beings. J Lab Clin Med 43:566, 1954.

Forssman O and Nordqvist P: The action in vitro and in vivo od sodium versenate on the phagocytic activity of neutrophile leukocytes. Acta Haemat 31:289, 1964.

Friedel W, Schulz FH and Schröder I: Arteriosclerosis therapy with mucopolysaccharides and EDTA. Deutsch Gesundh 20:1566, 1965.

Fromke VL, Lee MY and Watson CJ: Porphyrin metabolism during Versenate® therapy in lead poisoning. Intoxication from an unusual source. Ann Intern Med 70:1007, 1969.

Fuleihan FJD, Kurban AK, Abboud RT, Beidas-jubran N and Farah FS: An objective evaluation of the treatment of systemic scleroderma with disodium EDTA, pyridoxine and reserpine. Brit J Derm 80:184, 1968.

Ghiringhelli L and Respighi E: The tubular reabsorption of phosphorus during the test of parathyroid stimulation by versenate (test of Kaiser &Ponsold). Atti Acad Med Lombarda 18:191, 1963.

Ghiringhelli L, Marinoni E and Respighi E: Study of the parathyroid function by means of the Kaiser &Ponsold test in a group of thyroidectomized patients. Minerva Med 54:2829, 1963.

Gibbons HL: Edetate disodium calcium, calcium-channel blockers, and heart disease. JAMA 246:1728, 1981.

Godfrey ME: EDTA chelation as a treatment of arteriosclerosis NZ Med J 93:199, 1990.

Godfrey ME, Frackleton JP and Chappell LT: Chelation therapy for intermittent claudication (Letter). Z Med J 107:495, 1994.

Godfrey ME, Agnihotri R, and Strauss A: Chelation and arteriosclerosis. NZ Med J 101(838):21, 1988.

Goldsmith RE, King LR, Zalme E and Bahr GK: Serum calcium homeostasis in radioiodine treated thyrotoxic subjects as measured by ethylenediamine tetraacetate infusion. Acta Endocrin 58:565, 1968.

Gordon GB and Vance RB: EDTA chelation therapy for atherosclerosis: history and mechanisms of action. Osteopath Ann 4:38, 1976.

Gotto AM Jr: Chelation therapy in 1984. Texas Medicine 80:36, 1984.

Gould RG: Metals and chelating agents in relation to atherosclerosis. Fed Proc 20 (Suppl 10):252, 1961.

Grier MT and Meyers DG: So much writing, so little science: A review of 37 years of literature on edetate sodium chelation therapy. Ann Pharmacother 27:1504, 1993.

Guldager B, Jelnes R, Jorgenson SJ, et al: EDTA treatment of intermittent claudication - a double-blind placebo-controlled study. J Intern Med 231:261, 1992.

Gutteridge JMC: Ferrous-salt promoted damage to deoxyribose and benzoate, the increased effectiveness of hydroxyl-radical scavengers in the presence of EDTA. Biochem J 243:709, 19987.

Halstead BW: The scientific basis of EDTA chelation therapy. Colton, California, Golden Quill Publishers, 1979.

Hancke C and Flytlie K: Manipulation with EDTA. Ugeskr Laeger 154:2213, 1992.

Hancke C and Flytlie K: Benefits of EDTA chelation therapy on arteriosclerosis. J Adv Med 6:161, 1993.

Hansotia P, Peters H, Bennett M and Brown R: Chelation therapy in Wegener's granulomatosis. Treatment with EDTA. Ann Otol 78:388, 1969.

Hardy HL: Clinical experience with the use of calcium disodium ethylenediaminetetraacetate in the therapy of lead poisoning. Fed Proc 20 (Suppl 10):252, 1961.

Harper JW and Gordon GF: Reprints of medical literature on chelation therapy. Los Angeles, American Academy of Medical Preventics, 1975.

Haumont S and Vincent J: Action of calcium versenate on lead fixed in vivo in compact bone. Exp Cell Res 18:404, 1959.

Hausmann E: Changes in plasma phosphate concentration on infusion of calcium gluconate or Na2EDTA. Proc Soc Exp Biol Med 134:182, 1970.

Hay DR: Chelation therapy. N Z Med J 101(841):122, 1988.

Hay DR: Chelation therapy. N Z Med J 101(845):246, 1988.

Heath DA, Knapp MS and Walker WHC: Comparison between inulin and 51Cr-labelled edetic acid for the measurement of glomerular filtration-rate. Lancet 2:1110, 1968.

Heller J and Vostal J: Renal excretion of calcium-disodium-ethylenediamine-tetraacetic acid - a new tubular secretory mechanism? Experientia 20:99, 1964.

Herd JK and Vaughan JH: Calcinosis universalis complicating dermatomyositis - its treatment with Na2EDTA. Report of two cases in children. Arthritis Rheum 7:259, 1964.

Holland JF, Danielson E and Sahagian-Edwards A: Use of EDTA in hypercalcemic patients. Proc Soc Exp Biol Med 84:359, 1953.

Hösli P: Therapy of scleroderma with the disodium salt of ethylenediaminetetraacetic acid; a contribution to the toxicology of versenate. Part I. Arzneimittelforschung 10:65, 1960.

Hösli P: Therapy of scleroderma with the disodium salt of ethylenediaminetetraacetic acid; a contribution to the toxicology of versenate. Part II. Arzneimittelforschung 10:177, 1960.

Jick S and Karsh R: The effect of calcium chelation on cardiac arrhythmias and conduction disturbances. Am J Cardiol 4:287, 1959.

Johnson SAM: Use of the chelating agent edathamil disodium in acrosclerosis, sarcoidosis and other skin conditions with comments on tryptophan metabolism in sarcoidosis. Wisconson Med J 59:651, 1960.

Jonas WB: Meta-analysis of EDTA chelation: math that doesn't matter. J Adv Med 7:109, 1994.

Jonas WB: Effectiveness of EDTA chelation therapy. Circulation 5:1352, 1995.

Jones KH and Fourman P: Edetic-acid test of parathyroid insufficiency. Lancet 2:119, 1963.

Jones RJ: Chelation therapy (Letter). JAMA 250:672, 1983.

Julian JJ: Pass or Bypass? Chelation Extends Life. Hollywood, Wellness Press, 1981.

Kalliomaki JL, Markkanen TK and Mustonen VA: Serum calcium and phosphorous homeostasis in man studied by means of the sodium EDTA test. Acta Med Scan 170:211, 1961.

Kaman RL, Rudolph CJ, McDonagh EW and Walker FM: Effect of EDTA chelation therapy on aortic calcium in rabbits on atherogenic diets; quantitative and histochemical studies. J Adv Med 3:13, 1990.

Kebe SR: ACTH and a chelating agent for schizophrenia. West Med 4:46, 1963.

Klein R and Harris SB: Treatment of scleroderma, sclerodactylia and calcinosis by chelation (EDTA). Am J Med 19:798, 1955.

Kitchell JR, Meltzer LE, and Seven MJ: Potential uses of chelation methods in the treatment of cardiovascular diseases. Prog Cardiovasc Dis 3: 338, 1961.

Kitchell JR, Palmon F Jr, Aytan N, et al: The treatment of coronary artery disease with disodium EDTA. A reappraisal. Am J Card 11:501, 1963.

Kneller LA, Uhl HSM and Brem J: Successful calcium disodium ethylene diamine tetraacetate treatment of lead poisoning in an infant. N Engl J Med 252:338, 1955.

Koen A, McCann DS and Boyle AJ: Some in vivo effects of chelation. II. Animal experimentation. J Chron Dis 16:329, 1963.

Konradi MG: Use of disodium ethylenediaminetetraacetate test for diagnosing latnet forms of hypoparathyroidism. Prob Endokrinol 23:46, 1977.

Kozlov VA and Novikova VM: Calcium ion-dependent immunosuppressive effect of ethylenediaminetetraacetic acid (EDTA). Epidemiol Immunobiol 1:69, 1978.

Lamar CP: Chelation therapy of occlusive arteriosclerosis in diabetic patients. Angiology 15:379, 1964.

Lamar CP: Chelation endarterectomy for occlusive atherosclerosis. J Am Geriatrics Soc 15: 272, 1966.

Lamb DJ and Leake DS: The effect of EDTA on the oxidation of low density lipoprotein. Atherosclerosis 94:35, 1992.

Leipzig LJ, Boyle AJ and McCann DS: Case histories of rheumatoid arthritis treated with sodium or magnesium EDTA. J Chron Dis 22:553, 1970.

Leitner SA: Last chance to live. Wade Allen Publishing, Chesterfield, MO, 1980.

Lelievre P and Betz EH: Effect of versene on oxygen consumption of tissues in vitro. C R Soc Biol 155:199, 1961.

Liberman UA, Barzel U, De Vries A and Ellis H: Myositis ossificans traumatica with unusual course. Effect of EDTA on calcium, phosphorus and mangenese excretion. Am J Med Sci 254:35, 1967.

Lochte HL Jr, Ferrebee JW and Thomas ED: The effect of heparin and EDTA on DNA synthesis by marrow in vitro. J Lab Clin Med 55435, 1960.

Lockefeer JH, Hackeng WHL and Birkenhagër JC: Parathyroid hormone secretion in disorders of calcium metabolism studied by means of EDTA. Act Endocr 75:286, 1974.

Lonsdale D: EDTA chelation therapy (Letter). Am J Surg 166:316, 1993.

Luchi RJ, Helwig J Jr and Conn HL Jr: Quinidine txoicity and its treatment. An experimental study. Am Heart J 65:340, 1963.

Lyons RD: Chelation: miracle cure or false hope? Med J Aust 142: 519, 1985.

Magee HR: Chelation therapy for atherosclerosis (Letter). Med J Aust 143:127, 1985.

Magee R: Chelation treatment of atherosclerosis Med J Aust 142:514, 1985.

Malinovska V, Zechmeister A, Brucknerova E et al: Ultrahistochemical study of the effect of glucagon and Chelation III on arterial wall structure after experimental calcification. Folia Morphologica 28:20, 1978.

Marcelle R and Lecomte J: On the cardiovascular activities of the sodium salt of ethylenediaminetetraacetic acid. C R Soc Biol 153:1483, 1959.

Margolis S: Chelation therapy is ineffective for the treatment of peripheral vascular disease. Alternative Therapies Health Med 1:53, 1995.

Marlow CG and Sheppard G: [51Cr] EDTA, [hydroxymethyl-14C] inulin-T for the determination of glomerular filtration rate. Clin Chim Acta 28:479, 1970.

Marney SR Jr and Des Prez RM: Rabbit platelet injury by soluble antigen and antibody. III. Effects of the sodium and magnesium salts of EDTA and EGTA. J Immun 106:1446, 1971.

Marsh L and Fraser FC: Chelating agents and teratogenesis. (Letter) Lancet 1:846, 1973.

Maxwell GM, Elliot RB and Robertson E: The effect of Na3EDTA-induced hypocalcemia upon the general and coronary hemodynamics of the intact animal. Am Heart J 66:82, 1963.

Mayan H, Salomon O, Pauzner R, et al: EDTA-induced pseudothrombocytopenia. South Med J 85:213, 1992.

McCann DS, Koen Z, Zdybek G and Boyle AJ: Effect of chelation on phosphorus metabolism in experimental atherosclerosis. Circ Res 11:880, 1962.

McCoy JE, Carre IJ and Freeman M: A controlled trial of edathamil calcium disodium in acrodynia. Pediatrics 25:304, 1960.

McDonagh E, Rudolph, CJ, and Cheraskin E: An oculocerebrovasculometric analysis of the improvement in arterial stenosis following EDTA chelation therapy. J Holistic Med 4:21, 1982.

McDonagh EW, Rudolph CJ, and Cheraskin E: The effect of EDTA chelation therapy plus supportive multivitamin-trace mineral supplementation upon renal function: a study in serum creatinine. J Holistic Med 4:146, 1982.

McDonagh EW, Rudolph CJ, and Cheraskin E: Effect of EDTA chelation therapy plus multivitamin trace mineral supplementation upon vascular dynamics: ankle/brachial doppler systolic blood pressure ratio. J Holistic Med 7:16, 1985

McDonagh EW, Rudolph CJ, and Cheraskin E: The influence of EDTA salts plus multivitamin-trace mineral therapy upon total serum cholesterol/high-density lipoprotein cholesterol. Med Hypotheses 9:643, 1982.

McDonagh EW, Rudolph CJ, and Cheraskin E: The homeostatic effect of EDTA with supportive multivitamin trace mineral supplementation upon high-density lipoproteins (HDL). J Osteopath Phys Surg Calf 8: #2, Spring 1982.

McDonagh EW, Rudolph CJ, and Cheraskin E: The effect of intra-venous disodium ethylenediaminetetraacetic acid (EDTA) plus supportive multivitamin/trace mineral supplementation upon fasting serum calcium. Med Hypotheses 11:431, 1982.

McDonagh EW, Rudolph CJ, and Cheraskin E: The glycohemoglobin (HbA1c) distribution in EDTA-chelation-eligible patients. J Orthomolecular Psych 12:72, 1983.

McDonagh EW and Rudolph CJ: A Collection of Published Papers Showing the Efficacy of EDTA Chelation Therapy. Gladstone, MD, McDonagh Medical Center, 1991.

McDonagh EW: Chelation Can Cure: How to Reverse Heart Disease, Diabetes, Stroke, High Blood Pressure or Surgery. Kansas City, Platinum Pen Publications, 1983.

McGill WF: The effects of EDTA chelation therapy on plaque calcium and mineral metabolism in atherosclerotic rabbits. Dissertation Abstracts International Vol. 41, No. 04, October 1980.

McGillen M J and Mancini GBJ: Inefficacy of EDTA chelation therapy for coronary atherosclerosis. N Engl J Med 318:1618, 1988.

Mehbod H: Treatment of lead intoxication. Combined use of peritoneal dialysis and edetate calcium disodium. JAMA 201:972, 1967.

Meltzer LE: Chelation Therapy. In Seven MJ and Johnson LA (eds): Metalbinding in Medicine. Philadelphia, JB Lippincott, 1960.

Meltzer LE, Palmon FJ, and Kitchell JR: Hypoglycemia induced by disodium ethylenediamine tetra-acetic acid. Lancet 2:637, 1961.

Meltzer LE, Kitchell JR, and Palmon FJ: The long term use, side effects, and toxicity of disodium ethylenediamine tetraacetic acid (EDTA). Am J Med Sci 242:11, 1961.

Mischol HR and Wildbolz R: Instrumental chemolysis of renal calculi: Indications and dangers. J Urol 105:607, 1971.

Moel DI and Kunar K: Reversible nephrotoxic reactions to a combined 2,3-dimercapto-1-propanol and calcium disodium ethylenediaminetetraacetic acid regimen to asymptomatic children with elevated blood lead levels. Pediatrics 70:259, 1982.

Moncrieff AA, Koumides OP, Clayton BE, Patrick AD, Renwick AGC and Roberts GE: Lead poisoning in children. Arch Dis Child 39:1, 1964.

Müller SA, Brunstig LA and Winkelmann RK: The treatment of scleroderma with the new chelating agent edathamil. Arch Dermatol 3:305, 1962.

Mongan ES: The treatment of progressive systemic sclerosis with disodium edetate. Arthitis Rheum 8:1145, 1965.

Montgomery MR: Advances in medical fraud: chelation therapy replaces Laetrile. J Florida Med Assoc 73:681, 1986.

Morgan JM: Chelation therapy in lead nephropathy. South Med J 68:1001, 1973.

Myers HL: Topical chelation therapy for varicose pigmentation. Angiology 17:66, 1966.

Nakano J, Cole B and Ishii T: Effects of disodium EDTA on the cardiovascular responses to prostaglandin E1. Experientia 24:808, 1968.

Nayler WG: Ventricular arrhythmias following the administration of Na2EDTA. J Pharmacol Exp Ther 137:5, 1962.

Nedergaard OA and Vagne A: Effect of EDTA and other chelating agents on norepinephrine uptake by rabbit aorta in vitro. Proc West Pharmacol Soc 11:87, 1968.

Neldner KH, Winklemann RK and Perry HO: Scleroderma. An evaluation of treatment with disodium edetate. Arch Derm 86:305, 1962.

Nguyen-The-Minh: Treatment of digitalis intoxication with EDTA Na2. Presse Med 71:2385, 1963.

Nikitina EK and Abramova MA: Treatment of atherosclerosis with Trilone B (EDTA). Kardiologiia 12:137, 1972.

Nodine JH: Edetic acid therapy. (Letter) JAMA 212:628, 1970.

Offer GW: The antagonistic action of magnesium ions and ethylenediaminetetraacetate on myosin A ATPase (potassium activated). Biochim Biophys Acta 89:566, 1964.

Oliver LD, Mehta R and Saries HE: Acute renal failure following administration of ethylenediamine-tetraacetic acid (EDTA). Tex Med 80:40, 1984.

Olszewer E and Carter JP: EDTA Chelation therapy: a retrospective study of 2,870 patients. J Adv Med 27:197, 1989.

Olszewer E and Carter JP: EDTA chelation therapy in chronic degenerative disease. Med Hypotheses 27(1):41, 1988.

Olszewer E, Sabbag FC, and Carter JO: A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease. J Natl Med Assoc 82:173, 1990.

Olwin JH and Koppel JL: Reduction of elevated plasma lipid levels in atherosclerosis following EDTA therapy. Proc Soc Exp Biol Med 128:1137, 1968.

Ontka JA: Physical and chemical changes in isolated chylomicrons: prevention by EDTA. J Lipid Res 11:367, 1970.

Oser BL: Observations on the chronic ingestion of a chelating agent by rats and dogs. Fed Proc 20(Suppl 10):158, 1961.

Oser BL, Oser M and Spencer HC: Safety evaluation studies of calcium EDTA. Toxicol Appl Pharmacol 5:142, 1963.

Painter JT and Morrow EJ: Porphyria. Its manifestations and treatment with chelating agents. Texas State J Med 55:811, 1959.

Parfitt AM: Study of parathyroid function in man by EDTA. J Clin Endocr 29:569, 1969.

Patterson R: Chelation therapy and Uncle John. CMAJ 140(7):829, 1989.

Pavek K, Drinal J and Selecky FV: Circulatory effects of disodium edetate in digoxin-induced ventricular tachycardia. Cardiologia 50:297, 1967.

Payne BA and Pierre RV: Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences. Mayo Clinic Proc 59:123, 1984.

Payne JM and Sansom BF: The relative toxicity in rats of disodium ethylene diamine tetra-acetate, sodium oxalate and sodium citrate. J Physiol 170:613, 1964.

Peng CF, Kane JJ, Murphy ML and Straub KD: Abnormal mitochondrial oxidative phosphorylation of ischemic myocardium reversed by Ca2+-chelating agents. J Mole Cell Cardiol 9:897, 1977.

Pentel P, Jorgensen C, and Somerville J: Chelation therapy for the treatment of atherosclerosis, an appraisal. Minn Med Feb:101, 1984.

Perry HM Jr: Chelation therapy in circulatory and sclerosing diseases. Fed Proc 20 (Suppl 10):254, 1961.

Perry HM Jr and Schroeder HA: Depression of cholesterol levels in human plasma following ethylenediamine tetraacetate and hydralazine. J Chron Dis 2:520, 1955.

Perry HM Jr and Schroeder HA: Lesions resembling vitamin B complex deficiency and urinary loss of zinc produced by ethylenediamine tetraacetate. Am J Med 22:168, 1957.

Peters HA, Eichman PL and Reese HH: Therapy of acute, chronic and mixed hepatic porphyria patients with chelating agents. Neurology 8:621, 1958.

Peters HA, Johnson SAM, Cam S, Oral S, Müftü Y and Ergene T: Hexachlorobenzene-induced porphyria: Effect of chelation on the disease, porphyrin and metal metabolism. Am J Med Sci 251:314, 1966.

Peters HA: Trace minerals, chelating agents and the porphyrias. Fed Proc 20 (Suppl 10):227, 1961.

Peterson GR: Adverse effects of chelation therapy. (Letter) JAMA 250:2926, 1983.

Petrovic L, Stanovic M, Savicevic M and Poleti D: Aerosol inhaltion of CaNa2E.D.T.A. (mosatil) by workers constantly exposed to lead poisoning. Brit J Indust Med 17:201, 1960.

Platts-Mills A: EDTA chelation therapy. NZ Med J, 101(849):465, l988.

Popovici A, Geschickter CF, Reinovsky A and Rubin M: Experimental control of serum calcium levels in vivo. Proc Soc Exper Biol & Med 74:415, 1950.

Price JM: Some effects of chelating agents on tryptophan metabolism in man. Fed Proc 20 (Suppl 10):223, 1961.

Pullman TN, Lavender AR and Forland M: Synthetic chelating agents in clinical medicine. Ann Rev Med 14:175, 1963.

Rathmann KL and Golightly LK: Chelation therapy of atherosclerosis. Drug Intell Clin Pharm 18:1000, 1984.

Raymond JZ and Gross PR: EDTA: preservative dermatitis. Arch Derm 100:436, 1969.

Remagen W, Hiller FK and Sanz CM: Metabolic changes in experimental poisoning with ethylenediamine-tetraacetic acid. Arzneimittelforschung 11:1097, 1961.

Renoux M and Mikol C: Chelation. Presse Med 72:3117, 1964.

Reuber MD: Accentuation of Ca edetate nephrosis by cortisone. Arch Path 76:382, 1963.

Reuber MD and Bradley JE: Acute versenate nephrosis occurring as a result of treatment for lead intoxication. JAMA 174:263, 1960.

Reuber MD: Severe nephrosis in older male rats given calcium disodium edetate. Arch Environ Health 15:141, 1967.

Reuber MD: Calcium disodium edetate nephrosis in female rats of varying ages. J Path 97:335, 1969.

Reuber MD and Schmieler GC: Edetate kidneys lesions in rats. Arch Environ Health 5:430, 1962.

Reuber MD: Hepatic lesions in young rats given calcium disodium edetate. Toxicol Appl Pharmacol 11:321, 1967.

Reuter H, Niemeyer G and Gross R: The distribution of EDTA and citrate in blood and plasma. Throm Diath Haemorrh 19:213, 1968.

Rieders F, Dunnington WG and Brieger H: The efficacy of edathamil calcium disodium in the treatment of occupational lead poisoning. Indust Med 24:195, 1955.

Riordan HD, Cheraskin E, Dirks M, et al: EDTA chelation/hypertension study: clinical patterns as judged by the Cornell Medical Index Questionnaire. J Orthomolelcular Med 4:91, 1989.

Riordon HD, Cheraskin E, Dirks M, et al: Another look at renal function and the EDTA treatment process. J Ortho Med 2:185, 1987.

Riordon HD, Cheraskin E, Dirks M, et al: Electrocardiographic changes associated with EDTA chelation therapy. J Adv Med 1:191, 1988.

Robinson DM: Chelation therapy. N Z Med J 74:750, 1982.

Rosenbaum JL, Mason D and Seven MJ: The effect of disodium EDTA on digitalis intoxication. Am J Med Sci 240:77, 1960.

Rossi EC: Effects of ethylenediaminetetraacetic acid (EDTA) and citrate upon platelet glycolysis. J Lab Clin Med 69:204, 1967.

Rotota MC and Sanowski R: Acute intermittent porphyria. J Med Soc New Jersey 61:101, 1964.

Rubin M, Gignac S, Bessman SP and Belknap E: Enhancement of lead excretion in humans with EDTA. Science 117:659, 1953.

Rudolph CJ, McDonagh EW and Barber RK: The effect of EDTA chelation on serum iron. J Adv Med 4:39, 1991.

Rudolph CJ, McDonagh EW and Barber RK: A non-surgical approach to obstructive carotid stenosis using EDTA chelation. J Adv Med 4:157, 1991.

Rudolph CJ, Samuels RT and McDonagh EW: Visual field evidence of macular degeneration reversal using a combination of EDTA and multiple vitamin and trace mineral therapy. J Adv Med 7:203, 1994.

Rutman JZ, Melttzer LE, Kitchell JR, et al: Effect of metal ions on in vitro gluconeogensis in rat kidney cortex slices. Am J Physiol 208:841, 1965.

Sachs HK, Blanksma LA, Murray EF and O'Connell MJ: Ambulatory treatment of lead poisoning: report of 1,155 cases. Pediatrics 46:389, 1970.

Schroeder HA: A practical method for the reduction of plasma cholesterol in man. J Chron Dis 4:461, 1956.

Schroeder HA, Menhard EM and Perry HM Jr: Antihypertensive effects of metal binding agents. J Lab & Clin Med 23:416, 1955.

Schubert J: Chelation in medicine. Sci Am 214:40, 1966.

Schwartz SL, Hayes JR, Ide RS, et al: Studies of the neohrotoxicity of ethylene diaminetetraacetic acid, Biomed Pharm 15:377, 1966.

Schwartz SL, Johnson CB, and Doolan PD: Study of the mechanism of renal vacuologenesis induced in the rat by ethylenediaminetetraacetate. Mol Pharm 6:54, 1970.

Schwartz SL, Johnson CB, Hayes JR and Doolan PD: Subcellular localization of ethylenediaminetetraacetate in the proximal tubular cell by the rat kidney. Biochem Pharmacol 16:2413, 1967.

Scott PJ: Chelation therapy for degenerative vascular disease. N Z Med J 95:538, 1982.

Scott PJ. Chelation therapy: evolution or devolution of a nostrum? N Z Med J 101:109, 1988.

Sehnert KW, Claque AF, and Cheraskin E: The improvement in renal function following EDTA chelation and multivitamin trace mineral therapy: A study in creatinine clearance. Med Hypotheses 15:301, 1984.

Selander S: Treatment of lead poisoning. A comparison between the effects of sodium calcium edetate and penicillamine administered orally and intravenously. Brit J Indust Med 24:272, 1967.

Seto DSY and Freeman JM: Lead nephropathy in childhood. Am J Dis Child 107:337, 1964.

Seven MJ: Observations on the dosage of intravenous chelating agents. Antibiotic Med 5:251, 1958.

Shibata S: Toxicological studies of EDTA salt (sodium ethylenediamine tetra-acetate. Folia Pharmacol Japonica 52:113, 1956, and Chem Abst 51:9918, 1957.

Shrand H: Treatment of lead poisoning with intramuscular edathamil calcium-disodium. Lancet 1:310, 1961.

Silverglade A: Chelation clinics. Chest 87:274 1985.

Sloth-Nielsen J, Guldager B, Mouritzen C, et al: Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am J Surg 162:122, 1991.

Soffer A: Chelation Therapy. Charles C. Thomas, Springfield, IL, 1964.

Soffer A: Chelation therapy for arteriosclerosis. JAMA 233:1206, 1975.

Soffer A: Chihuahuas and laetrile, chelation therapy, and honey from Boulder, Colo. Arch Intern Med 136:865, 1976.

Soffer A: Chelation clinics, an abuse of the physician's freedom of choice. Chest 86:157, 1984.

Soffer A and Toribara T: Changes in serum and spinal fluid calcium effected by disodium ethylenediaminetetraacetate. J Lab Clin Med 58:542, 1961.

Soffer A, Toribara T and Sayman A: Myocardial responses to chelation. Brit Heart J 23:690, 1961.

Soffer A, Toribara T, Moore-Jones D and Weber D: Clinical applications and untoward reactions and untoward reactions of chelation in cardiac arrhythmias Arch Inten Med 106:824, 1960.

Spence JD: Chelation therapy for intermittent claudication. ACP Journal Club, July/August page 8, 1992.

Spencer H, Greenberg J, Berger E et al: Studies of the effect of ethylenediaminetetraacetic acid in hypercalcemia. J Lab Clin Med 47:29, 1956.

Spencer H, Vankinscott V, Lewin I and Laszlo D: Removal of calcium in man by ethylenediamine tetra-acetic acid. A metabolic study. J Clin Invest 31:1023, 1952.

Stacey BD and Thorborn GD: Chromium-51 ethylenediaminetetraacetate for estimation of glomerular filtration rate. Science 152:1076, 1966.

Stamp TCB, Stacey TE and Rose GA: Comparison of glomerular filtration rate measurements using inulin, 51Cr-EDTA, and a phosphate infusion technique. Clin Chim Acta 30:351, 1970.

Stamp TCB: 51Cr-edetic-acid clearance and G.F.R. (Letter) Lancet 2:1348, 1968.

Stecker RH and Bennett M: Chelation in clinical otosclerosis. Arch Otolaryng 70:627, 1959.

Steven FS: The effect of chelating agents on collagen interfibrillar matrix interactions in connective tissue. Biochim Biophys Acta 140:522, 1967.

Stevenson JG and Covington TR: Chelation therapy in atherosclerosis. Ann Intern Med 97:789, 1982.

Surawicz B, MacDonald MG, Kaljot V, et al: Treatment of cardiac arrhythmias with salts of ethylenediamine tetraacetic acid (EDTA). Am Heart J 58:493, 1959.

Surawicz B: Use of the chelating agent, EDTA, in digitalis intoxication and cardiac arrhythmias. Prog Cardiovasc Dis 2:432, 1960.

Swenerton H and Hurley LS: Teratogenic effects of a chelating agent and their prevention by zinc. Science 173:62, 1971.

Szekely P and Wynne NA: Effects of calcium chelation on digitalis-induced cardiac arrhythmias. Brit Heart J 25:589, 1963.

Tate SS: Effect of metal ions and EDTA on the activity of rabbit liver fructose 1,6-diphosphatase Biochim Biophys Res Commun 24:662, 1966.

Teisinger J: Biochemical responses to provocative chelation by edetate disodium calcium. Arch Environ Health 23:280, 1971.

Thompson LJ: Chelation therapy. N Z Med J 103:326, 1990.

Timmermann A and Kallistratos G: Chemotherapy in nephrolithiasis. Isr J Med Sci 7:689, 1971.

Timmermann A and Kallistratos G: Modern aspects of chemical dissolution of human renal calculi by irrigation. J Urol 95:469, 1966.

Traub YM, Samuel R, Lubin E, Lewitus Z and Rosenfeld JB: A comparison between the clearances of inulin, endogenous creatinine, and 51Cr-EDTA. Isr J Med Sci 9:487, 1973.

Trowbridge JP and Walker M: Chelation Therapy: The Key to Unclogging Your Arteries, Improving Oxygenation, Treating Vision Problems. 3rd Ed. Marble Falls, Texas, Better Health Booklet Service, 1990.

Tsang RC, Chen I-W and McEnerg P: Parathyroid function tests with EDTA infusions in infancy and childhood. J Pediatr 88:250, 1976.

Uhl HSM, Brown HH, Zlatkis A, Zak B, Myers GB and Boyle AJ: Effect of ethylenediamine tetraacetic acid on cholesterol metabolism in rabbits. Am J Clin Path 23:1226, 1950.

Van der Schaar P: Exercise tolerance in chelation therapy. J Adv Med 2:563, 1989.

van Rij AM, Solomon C, Packer SGK, et al: Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. Circulation 90:1194, 1994.

van Rij AM, Solomon C, Packer SGK and Hopkins WG: [Chelation therapy] Response (Letter). Circulation 5:1350, 1995.

van Rij AM, Solomon C, Packer SGK and Hopkins WG: [Effectiveness of EDTA chelation therapy] Response (Letter). Circulation 5:1352, 1995.

Vogt W and Cottier H: Nekrotisierende Nephrose nach Behandlung einer subakutchronischen Bleivergiftung mit Versenat in hohen Dosen. Schweiz Med Wchnschr 87:665, 1957.

Walker FMcG: The effects of EDTA chelation therapy on plaque calcium and mineral metabolism in atherosclerotic rabbits. Physiology (Dissertation Abstracts International) Vol. 41, No. 04, 1980.

Walker M: How to Prevent or Reverse Hardening of the Arteries in Chelation Therapy. M Evans Co, Inc., New York, 1981.

Walker M: The Miracle Healing Power of Chelation Therapy. Canfield, Ohio, Fischer Publishing, 1984.

Walker M: The Chelation Way: The Complete Book of Chelation Therapy. Garden City Park, NY, Avery Publishing, 1990.

Walker M: Chelation therapy: how to prevent or reverse hardening of the arteries. Atlanta, '76 Press, 1987.

Walker M and Gordon G: The chelation Answer. Atlanta, '76 Press, 1983.

Wartman A, Lampe TL, McCann, DS, et al: Plaque reversal with MgEDTA in experimental atherosclerosis: Elastin and collagen metabolism. J Athero Res 7:331, 1967.

What is chelation therapy for arteriosclerosis? Br Med J 285: 1982.

Whitaker J: You have alternatives to bypass surgery. Health Healing Lett Feb, 1993.

Whitaker JA, Austin W and Nelson JD: Edathamil calcium disodium (Versenate) diagnostic test for lead poisoning. Pediatrics 29:384, 1962.

Wilder LW, DeJode LR, Milstein, SW, et al: Mobilization of atherosclerotic plaque calcium with EDTA utilizing the isolation-perfusion principle. Surgery 52:793, 1962.

Williams JD, Matthews GA and Judd AW: Oral calcium disodium versenate in treatment of lead poisoning. Brit J Indust Med 19:211, 1962.

Winder PR and Curtis AC: Edathamil in the treatment of scleroderma and calcinosis cutis. Arch Derm 82:732, 1960.

Wirebaugh SR and Geraets DR: Apparent failure of edetic acid chelation therapy for the treatment of coronary atherosclerosis. DICP Ann Pharm 24:22, 1990.

Woods SM, Peters HA and Johnson SAM: Chelation therapy in cutaneous porphyria. A review and report of a five-year recovery. Arch Derm 84:920, 1961.

Wynn JE, Riet B, Van't and Borzelleca JF: The toxicity and pharmacodynamics of EGTA: oral administration to rats and comparisons with EDTA. Toxicol Appl Pharmacol 16:807, 1970.

Yang WC: Stimulatory effect of EDTA on cardiac mitochondrial respiration. Biochem Biophys Res Commun 2:22, 1960.

TOP OF PAGE

Copyright © 2012 Elmer M. Cranton, M.D., all rights reserved

Last modified: